Evidence Based Management of Cancers in India 24-26 Feb 2017
Scientific programme highlights - symposia, debates and discussions
AGenomics and precision medicine
•Has the molecular revolution reached the bedside?
•How much of genomic data has translated into clinical practice?
•Has targeted therapy fulfilled its promise? (debate)
•Is precision medicine an achievable goal? (debate)
BNew ideas in clinical oncology
•Therapeutic strategies to harness the peri-operative window
•Biological principles of metronomic therapy
•Targeting copper to treat breast cancer
•Novel PI3 kinase inhibitor: from bench to bedside
CNew ideas in basic research
•Cancer as an infectious disease caused by dead-cell chromatin
•Clinical implications of apoptotic circulating tumour cells
•Cancer: but which cell is it anyway?
•Cancer metastasis: which cell is it anyway?
•Dead cell chromatin, tumour heterogeneity and therapy resistance
DCancer data analysis
•Omics and big data sets: out of control?
•How relevant are the randomized controlled clinical trials in clinical practice?
EPublic health and cancer statistics
•Harms of cancer screening
•Problems and pitfalls in public health research
•Challenges of HPV vaccination
FThe lure of technology
•Harnessing technology for cancer treatment, who benefits?
•The politics and economics of novel technologies
•Advanced technologies and global cancer outcome
GHospital day oration and special lectures
•Prometheus bound - stalling innovation in successful societies
•Cancer research in need of a scientific revolution
•Thinking Outside the Box in Cancer Research: Perspectives from the US NCI
•Future of Oncology: European perspective
•Fractal geometry in oncogenesis
•Should the industry reconsider its approach to cancer drug development?
H‘Top abstracts’ session
•A 90 minute session highlighting the key messages from various talks and discussions during the conference and also deliberate a possible cancer agenda for the future. Panelists will include senior faculty, key note speakers and international policy makers.